530 Results

People

  1. Drilon
    Drilon
  2. Ladanyi
    Ladanyi
  3. Kris
    Kris
  4. Hyman
    Hyman
  5. Riely
    Riely
  6. Li
    Li
  7. Offin
    Offin
  8. Arcila
    Arcila
  9. Schram
    Schram
  10. Benayed
    Benayed

Groups

  1. Department of Medicine (530)
  2. Solid Tumor Oncology Division (530)
  3. Thoracic Oncology (530)
  4. GSK Faculty (168)
  5. Human Oncology and Pathogenesis Program (145)
  6. Tow Center for Developmental Oncology (TCDO) (117)
  7. Early Drug Development Service (105)
  8. Sloan Kettering Institute Postdocs (85)
  9. Epidemiology and Biostatistics (64)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (63)
  1. "Alexander Drilon"
  2. "Thoracic Oncology"
Formats
  1. Meeting Abstract (320)
  2. Journal Article (182)
  3. Review (17)
  4. Editorial (5)
  5. Book Section (2)
  6. Book Whole (1)
  7. Correspondence (1)
  8. Guidelines (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (530)
  2. Solid Tumor Oncology Division (530)
  3. Thoracic Oncology (530)
  4. GSK Faculty (168)
  5. Human Oncology and Pathogenesis Program (145)
  6. Tow Center for Developmental Oncology (TCDO) (117)

More Groups

People
  1. Alexander Drilon (530)
  2. Marc Ladanyi (111)
  3. Mark Kris (81)
  4. David Hyman (77)
  5. Maria Arcila (76)
  6. Gregory Riely (60)

More People

Years
  1. 2023 (44)
  2. 2022 (85)
  3. 2021 (76)
  4. 2020 (81)
  5. 2019 (76)
  6. 2018 (55)

More Years

Publications
  1. Journal of Clinical Oncology (121)
  2. Journal of Thoracic Oncology (74)
  3. Annals of Oncology (73)
  4. Clinical Cancer Research (29)
  5. Cancer Research (23)
  6. Oncology Research and Treatment (20)

More Publications

Publishers
  1. American Society of Clinical Oncology (140)
  2. Elsevier Inc. (103)
  3. Oxford University Press (86)
  4. American Association for Cancer Research (68)
  5. Nature Publishing Group (24)
  6. S. Karger AG (20)

More Publishers

Results (530)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2 study of REGN5093-M114, a METxMET antibody-drug conjugate, in patients with MET-overexpressing NSCLC
    Meeting Abstract

    Drilon, A.; Awad, M. M.; Camidge, D. R.; Forde, P. M.; Alexander, M.; Gadgeel, S. M.; Villaruz, L. C.; Perez, J.; Navas, T.; Daly, C.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Frequency and outcomes of leptomeningeal metastases in patients with fusion-positive lung cancers
    Meeting Abstract

    Chen, M.; Sui, J.; Wilcox, J.; Yang, S. R.; Imber, B.; Offin, M.; Yu, H.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Beware: Tyrosine kinase inhibitors for lung cancers that inhibit MATE-1 can lead to "False" decreases in renal function
    Meeting Abstract

    Chen, M.; Harada, G.; Liu, D.; Dematteo, R.; Falcon, C.; Wilhelm, C.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Brain metastases in patients with fusion-positive lung cancers
    Meeting Abstract

    Sui, J. S.; Chen, M. F.; Wilcox, J.; Yang, S. R.; Li, B. T.; Riely, G. J.; Offin, M.; Yu, H. A.; Kris, M. G.; Drilon, A. E.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of patients with EGFR-mutant lung cancer with acquired BRAF alterations
    Meeting Abstract

    Sui, J.; Yang, S. R.; Bowman, A. S.; Vankayala, P.; Falcon, C.; Somwar, R.; Drilon, A. E.; Riely, G. J.; Kris, M. G.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Microsatellite instability defines a subset of lung cancers with smoking exposure, high tumor mutational burden and MLH1 inactivation
    Meeting Abstract

    Yang, S. R.; Gedvilaite, E.; Ptashkin, R.; Chang, J.; Ziegler, J.; Mata, D.; Villafania, L. B.; Nafa, K.; Hechtman, J. F.; Benhamida, J.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Predictive biomarkers of response to REGN5093 to guide patient selection in MET-altered advanced non-small cell lung cancer
    Meeting Abstract

    Navas, T.; Drilon, A. E.; Cho, B. C.; Viau, J.; Tao, W.; Zhu, Y. O.; Giangreco, N.; Perez, J.; Masinde, S.; Paccaly, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Real-world landscape analysis of activating ERBB2/ERBB3 alterations in 107,561 tissue and plasma samples from patients with NSCLC
    Meeting Abstract

    Liu, D.; Jee, J.; Keller, R. B.; Schrock, A. B.; Drilon, A.; Oxnard, G. R.; Li, B. T.
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Activating MET tyrosine kinase domain mutations as de novo oncogenic drivers in non-small cell lung cancer
    Meeting Abstract

    Nakazawa, S.; Pecci, F.; Ricciuti, B.; Harada, G.; Lee, J. K.; Alessi, J. V.; Barrichello, A. P. C.; Vaz, V. R.; Lamberti, G.; Di Federico, A.; more...
    Journal of Thoracic Oncology (2023)

    Fulltext@MSK | Save
  • Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis
    Meeting Abstract

    AndreĢ, T.; Hong, D.; Deeken, J.; Italiano, A.; Liu, T.; Burcoveanu, D.; Norenberg, R.; Mussi, C.; Xu, R.; Drilon, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save